Immunic, Inc. (IMUX)
Stock Price:
$20.34 USD
1.64 (8.77%)
Updated Aug 10, 2020 11:40 AM EDT - Market open
Key Info
| Market Cap |
406.16M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-39.11M |
| Shares Out |
14.97M |
| EPS (ttm) |
-3.28 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 10, 2020 |
| Last Price |
$20.34 |
| Previous Close |
$18.70 |
| Change ($) |
1.64 |
| Change (%) |
8.77% |
| Day's Open |
19.05 |
| Day's Range |
18.71 - 20.50 |
| Day's Volume |
436,521 |
| 52-Week Range |
4.19 - 23.39 |
More Stats
| Market Cap |
406.16M |
| Enterprise Value |
388.05M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
14.97M |
| Float |
10.79M |
| EPS (basic) |
-3.69 |
| EPS (diluted) |
-3.28 |
| FCF / Share |
-3.34 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
132,808 |
| Short Ratio |
0.38 |
| Short % of Float |
1.84% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
3.43 |
| Revenue |
n/a |
| Operating Income |
-41.38M |
| Net Income |
-39.11M |
| Free Cash Flow |
-35.86M |
| Net Cash |
18.11M |
| Net Cash / Share |
0.91 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-36.86% |
| ROE |
-48.42% |
| ROIC |
2,808.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (5)
| Buy |
5 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$60.00*
(194.99% upside)
Low
57.0
Current: $20.34
High
64.0
Target: 60.00
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | - | - | - | - | - | - | - | - |
| Operating Income | -37.03 | -12.00 | -52.66 | -41.27 | -52.12 | -50.34 | -31.40 | -9.58 |
| Net Income | -34.93 | -11.54 | -52.08 | -40.97 | -52.02 | -47.67 | -32.72 | -6.70 |
| Shares Outstanding | 7.72 | 0.85 | 1.00 | 0.78 | 0.63 | 0.40 | 0.01 | 0.01 |
| Earnings Per Share | -4.52 | -13.63 | -52.40 | -52.40 | -82.80 | -141.60 | -2,994.40 | -715.60 |
| Operating Cash Flow | -28.55 | -9.74 | -40.40 | -35.77 | -49.95 | -40.83 | -28.65 | -9.24 |
| Capital Expenditures | -0.02 | -0.03 | -0.68 | -0.55 | -2.34 | -1.41 | -1.48 | -0.24 |
| Free Cash Flow | -28.56 | -9.77 | -41.08 | -36.33 | -52.29 | -42.23 | -30.13 | -9.49 |
| Cash & Equivalents | 29.37 | 13.07 | 56.90 | 59.99 | 83.95 | 104 | 39.15 | 18.83 |
| Total Debt | 0.52 | - | - | - | - | - | - | - |
| Net Cash / Debt | 28.85 | 13.07 | 56.90 | 59.99 | 83.95 | 104 | 39.15 | 18.83 |
| Assets | 65.96 | 13.37 | 60.38 | 64.03 | 89.08 | 108 | 46.59 | 20.33 |
| Liabilities | 7.59 | 1.92 | 10.34 | 5.58 | 6.76 | 10.52 | 91.24 | 27.96 |
| Book Value | 58.36 | -25.74 | 50.04 | 58.45 | 82.33 | 97.56 | -44.66 | -7.63 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Immunic, Inc. |
| Country |
United States |
| Employees |
26 |
| CEO |
Daniel Vitt |
Stock Information
| Ticker Symbol |
IMUX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: IMUX |
Description
Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis. The company is also developing IMU-935, an inverse agonist of RORyt; and IMU-856 for the restoration of the intestinal barrier function. Immunic, Inc. is headquartered in San Diego, California.